Intellectual Property Rights and Sustainable Development: Balancing Innovation and Access

Every life-saving medicine, drought-resistant seed, and clean-energy device begins as an idea. Intellectual Property Rights (IPR) decide who owns that idea, who can use it, and at what price. This creates a genuine dilemma for sustainable development. Strong IPR rewards inventors and pushes innovation forward, but the same protection can lock essential technologies behind high prices and legal walls. The question that runs through global trade law, public health, and agriculture is simple to ask and hard to answer: how do we reward the people who innovate while making sure everyone can access what they create?

What intellectual property rights actually protect 🔗

Intellectual property is a legal category for creations of the mind. It covers patents on inventions, copyrights on creative and software works, trademarks on brands, geographical indications on region-specific goods, trade secrets, and protection for new plant varieties. The logic behind it is economic. Developing a new drug or a new technology costs enormous money and time. If a competitor could copy the result instantly, the original inventor would never recover that investment. So the law grants a temporary monopoly. A patent, for example, gives the holder exclusive rights for a minimum of 20 years, during which others cannot make or sell the invention without permission.

This monopoly is meant to be a bargain with society. The inventor gets exclusive rights for a limited period. In return, the invention is publicly disclosed and eventually enters the public domain for everyone to use. On paper, the system rewards innovation and spreads knowledge. In practice, the period of exclusivity is exactly when prices stay high and access stays limited, and that is where the tension with sustainable development begins.

The core tension: innovation versus access 🔗

Sustainable development depends on getting useful technologies to the people who need them. Affordable medicines improve public health. Quality seeds support food security. Clean technologies help cut emissions. But the very protection that encourages companies to invest in these technologies also raises their cost and restricts their spread.

Consider the patent monopoly from the side of someone who needs the product. During the patent period, the holder can set prices freely. For a cancer patient, a farmer, or a government running a vaccination drive, that price can be the difference between access and exclusion. Developed countries, home to most large patent holders, tend to favour strong protection because it sustains research-heavy industries. Developing countries, with large low-income populations, often argue that the same rules block access to essentials and widen inequality. This is not a clash of good and bad intentions. It is a structural trade-off between two legitimate goals.

TRIPS: setting a global floor for intellectual property 🔗

The Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) came into force in 1995 under the World Trade Organization (WTO). It is the most important international treaty on IPR. Before TRIPS, protection varied widely between countries. TRIPS changed that by setting minimum standards that every WTO member must follow, covering patents, copyrights, trademarks, trade secrets, geographical indications, industrial designs, and plant varieties.

TRIPS was not designed only to protect rights holders. Its stated objectives include a clear balancing principle. Article 7 says that the protection of intellectual property should contribute to technological innovation and to the transfer and dissemination of technology, for the mutual benefit of producers and users, in a way that supports social and economic welfare. Article 8 goes further, allowing members to adopt measures to protect public health and nutrition and to serve the public interest in sectors vital to their development.

The balancing language inside TRIPS 🔗

These objectives matter because they give countries legal room to act in the public interest. TRIPS also recognised that not every country could meet the same standards overnight. Developing and least-developed nations were given longer transition periods to comply, especially for pharmaceutical and biotechnology patents. The treaty therefore tries to combine a firm global floor for protection with built-in space for flexibility. Whether that space is wide enough remains one of the most active debates in international trade.

Flexibilities that protect the public interest 🔗

The most important tools for balancing innovation and access are the flexibilities written into TRIPS. These are legal mechanisms that let governments limit the effect of a patent when public welfare is at stake.

Compulsory licensing 🔗

A compulsory licence allows a government to let a third party produce a patented product without the patent holder’s consent, usually in return for a royalty. It is used when a product is unaffordable, unavailable, or not being supplied to meet public need. The patent holder keeps the patent and is still paid, but loses the absolute monopoly.

The most cited example is India’s first compulsory licence, granted in 2012. The drug maker Bayer held a patent on Nexavar, a treatment for advanced liver and kidney cancer, and priced a month’s course at roughly 2.8 lakh rupees. The Indian company Natco Pharma applied for a compulsory licence and offered to supply the same drug for around 9,000 rupees a month. The Controller of Patents granted the licence, finding that Bayer had failed to make the drug available to the public at a reasonable price and had not worked the patent adequately in the country. The decision was upheld on appeal and became a model studied across the developing world. The legal basis for such action was reinforced by the 2001 Doha Declaration, which affirmed that TRIPS should be interpreted to support members’ right to protect public health and promote access to medicines.

Limiting evergreening 🔗

A second safeguard targets a practice called evergreening, where companies make minor modifications to an existing drug to extend patent protection beyond the original term. Section 3(d) of the Indian Patents Act blocks patents on new forms of known substances unless they show a significant improvement in efficacy. This provision was at the heart of the well-known Novartis case over the cancer drug Glivec, where the Supreme Court refused a patent on a modified version of an existing molecule. Studies of these decisions describe them as deliberate uses of TRIPS flexibilities meant to keep patents tied to genuine innovation rather than incremental tweaks.

Intellectual property and agriculture: seeds, farmers, and food security 🔗

Agriculture shows the access debate in its sharpest form because the technology in question is the seed itself. TRIPS Article 27.3(b) requires members to protect plant varieties, but it offers a choice. Countries can use patents, an effective sui generis system, or a combination of both. A sui generis system is a custom-built legal framework designed for something that does not fit existing categories.

India chose not to allow patents on plants. Instead it enacted the Protection of Plant Varieties and Farmers’ Rights (PPV&FR) Act, 2001, a sui generis law tailored to its own farming reality. The Act protects the rights of commercial plant breeders so they have an incentive to invest in research. At the same time, it explicitly protects farmers’ rights to save, use, exchange, and even sell farm-saved seed of a protected variety, as long as it is not sold under a branded package. This matters enormously in a country where a very large share of farming households still rely on saved seeds.

India also deliberately stayed outside the strict UPOV 1991 framework favoured by many developed countries, which limits seed-saving in ways that would have hurt small farmers. Analysts describe the PPV&FR Act as an attempt to align trade obligations with food security, biodiversity, and the livelihoods of millions of smallholders, directly connecting IPR design to the Sustainable Development Goals.

Manufacturing, information products, and technology transfer 🔗

Beyond medicine and agriculture, IPR shapes access to manufacturing know-how and information goods. Green technologies for renewable energy and climate adaptation are often patented in developed economies, which can slow their transfer to the countries that need them most. The TRIPS objectives promise technology transfer to developing nations, but in practice this transfer has been uneven, partly because of weak infrastructure and limited skilled personnel in poorer countries, and partly because rights holders have little commercial reason to share.

Information products raise their own questions. Copyright protects software, databases, educational material, and digital content. Strong copyright supports creative and software industries, yet it can also restrict access to knowledge, learning tools, and research, which are central to long-term development. The system was largely designed in a pre-digital era and is now being tested by artificial intelligence, gene editing, and data-driven products.

Global emergencies have sharpened these debates. During the COVID-19 pandemic, many countries pushed for a temporary waiver of certain patent rights on vaccines and treatments, arguing that exclusive protection was blocking equitable access during a crisis. The episode showed both the strength of the IPR system and the pressure it faces when public need collides with private rights.

Designing flexible IPR systems for sustainable development 🔗

The lesson running through these examples is that rigid, one-size-fits-all protection rarely serves sustainable development well. Flexible systems work better. This means using the safeguards that TRIPS already permits, such as compulsory licensing, anti-evergreening rules, and sui generis frameworks, while pursuing genuine technology transfer rather than treating it as an afterthought.

Innovation and access are not opposites that must cancel each other out. A well-designed IPR regime keeps enough reward in the system to attract investment in the technologies society needs, while keeping enough flexibility to ensure those technologies actually reach people. Striking that balance is not a one-time settlement. It is an ongoing negotiation that shifts with every new drug, seed, and digital tool, and it sits at the centre of how the world pursues development that is both innovative and fair.

What do you think? Should public health and food security always be allowed to override patent monopolies, or does weakening protection risk drying up the investment that produces new technologies in the first place? And in a world of artificial intelligence and gene editing, do the flexibilities written into TRIPS in the 1990s still go far enough?

References

1. https://www.wto.org/english/tratop_e/trips_e/intel2_e.htm
2. https://www.wto.org/english/docs_e/legal_e/27-trips_03_e.htm
3. https://journals.sagepub.com/doi/abs/10.1177/2455133315612321
4. https://journals.law.harvard.edu/ilj/wp-content/uploads/sites/84/561Liu.pdf
5. https://jmsr-online.com/article/farmers-rights-market-access-and-social-justice-an-analysis-of-india-s-plant-variety-protection-regime-470/